AMIX AUTONOMIX MEDICAL INC

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company’s recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial.

The CEO Corner segment is now available .



About Autonomix Medical, Inc.



Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit and connect with the Company on , , and .



Investor and Media Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
07/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AUTONOMIX MEDICAL INC

 PRESS RELEASE

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segme...

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company’s recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial. The CEO Corner segment is now available .About Autonomix Medical, Inc...

 PRESS RELEASE

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expan...

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies t...

 PRESS RELEASE

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the U...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Hu...

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix’s strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or ...

 PRESS RELEASE

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Cathete...

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix’s intellectual property position in the nerve-mapping and denervation space, supporting the Company’s broader mission to advance minimally invasive, nerve-focused therapeutics Company continues to expand its growing global patent portfolio with over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, May 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerv...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch